February 13, 20264 min read
GLP-1 medications are known for weight loss, but research shows meaningful effects on heart, kidney, and metabolic health. For women navigating perimenopause and menopause, understanding the bigger picture matters.
GLP-1 medications are often talked about as weight loss drugs. But when you look at the research more closely, the conversation becomes broader and even more interesting. Large clinical trials have shown effects on heart health, kidney function, and metabolic markers. For women navigating perimenopause and menopause, that matters.
This article is not medical advice. It is a plain language look at what researchers have studied so far, and how this may relate to midlife health.
Many women notice that something shifts in their 40s and 50s. Weight redistributes and often belly fat increases. Blood pressure creeps up and cholesterol numbers change. Many women experience fluctuations in energy.
Part of this is connected to declining estrogen. Estrogen plays a role in:
When estrogen declines, the body often stores more fat around the abdomen. This type of fat, called visceral fat, is more closely associated with cardiovascular and metabolic risk than fat stored elsewhere.
While lifestyle remains foundational, biology also plays a role.
GLP-1 is a hormone your body naturally produces. It helps regulate blood sugar and appetite. GLP-1 medications are designed to mimic this hormone. They were first developed to treat type 2 diabetes but over time, researchers began noticing additional effects.
Today, several GLP-1 medications are approved for diabetes and chronic weight management.
Some of the most significant findings come from cardiovascular outcome trials.
In large randomized studies involving thousands of participants:
It is important to note that many of these studies involved individuals at elevated cardiovascular risk. Results cannot automatically be generalized to everyone.
More recently, research has shown that GLP-1 medications may slow progression of kidney disease in people with diabetes and chronic kidney disease. In one major trial, the benefit was strong enough that the study was stopped early because it was deemed unethical to continue with placebo.
Again, these findings apply primarily to high risk populations. They are encouraging, but context matters.
Weight loss is often the visible outcome. But researchers also measure:
In insulin resistant individuals, improvements in these markers have been observed. For midlife women, this may be relevant because insulin resistance tends to increase during and after the menopausal transition. This does not mean GLP-1 is appropriate for everyone, but it does mean metabolic health deserves attention.
There is growing research exploring whether GLP-1 medications influence inflammation and brain health. Some studies have observed reductions in inflammatory markers such as hsCRP. Observational data has suggested potential associations with lower rates of cognitive decline. However, these findings are still being studied. It would be premature to describe GLP-1 as a brain protective or anti inflammatory therapy. The science is still evolving.
Hormonal health and metabolic health often intersect. Estrogen influences lipid levels, blood vessels, and fat distribution. For some women, appropriately prescribed hormone therapy may help address symptoms of perimenopause or menopause and may support certain cardiovascular markers when started at the right time under medical supervision.
There are currently no large trials specifically studying the combination of GLP-1 and hormone therapy as a unified protocol. However, in real world care, clinicians sometimes consider both metabolic and hormonal factors when building individualized treatment plans. What matters most is personalization.
GLP-1 medications are not:
They are prescription medications that require medical evaluation, screening, and follow up. For midlife women experiencing both hormonal and metabolic changes, the conversation is often larger than weight alone. The right approach begins with assessment and informed discussion.
The research around GLP-1 medications is expanding rapidly. Strong evidence supports cardiovascular benefit in high risk populations. Kidney protection has been demonstrated in specific groups. Metabolic improvements are well documented. Other areas, including inflammation and brain health, remain under active investigation.
For women in midlife, the most important question is not “Is this trending?” but “Is this appropriate for me?”
That answer should always come from a licensed clinician who understands your history, risk profile, and goals.
Midlife health is complex. The conversation should be too.
Sources
Wilding JPH et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med. 2021.
Drucker DJ.Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.Cell Metab. 2018.
Marso SP et al.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2016.
Marso SP et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med. 2016.
Gerstein HC et al.Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND).Lancet. 2019.
Perkovic V et al.Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.N Engl J Med. 2024.
Davis SR et al.Menopause.Nat Rev Dis Primers. 2015.
El Khoudary SR et al.Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention.Circulation. 2020.
Hemma Wellness is not a medical practice. All clinical services are provided by licensed healthcare professionals through our partner network. Individual results may vary.
These statements have not been evaluated by the Food and Drug Administration. Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality. This content is intended for informational purposes only and does not constitute medical advice.
Labs are billed separately when ordered by your clinician, except where noted in specific program descriptions.
